A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?

Veronica Villani; Alessandra Fabi; Antonio Tanzilli; Francesco Pasqualetti; Giuseppe Lombardi; Antonello Vidiri; Alessandra Gonnelli; Alessandro Molinari; Martina Cantarella; Luisa Bellu; Irene Terrenato; Mariantonia Carosi; Marta Maschio; Stefano Maria Telera; Carmine Maria Carapella; Francesco Cognetti; Fabiola Paiar; Vittorina Zagonel; Andrea Pace

doi:10.2217/fon-2018-0826

A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?

Veronica Villani, Alessandra Fabi, Antonio Tanzilli, Francesco Pasqualetti, Giuseppe Lombardi, Antonello Vidiri, Alessandra Gonnelli, Alessandro Molinari, Martina Cantarella, Luisa Bellu, Irene Terrenato, Mariantonia Carosi, Marta Maschio, Stefano Maria Telera, Carmine Maria Carapella, Francesco Cognetti, Fabiola Paiar, Vittorina Zagonel, Andrea Pace

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.

Original language	English
Pages (from-to)	1717-1727
Number of pages	11
Journal	Future Oncology
Volume	15
Issue number	15
DOIs	https://doi.org/10.2217/fon-2018-0826
Publication status	Published - May 1 2019

Keywords

bevacizumab
clinical benefit
glioma

Access to Document

10.2217/fon-2018-0826

Cite this

Villani, V., Fabi, A., Tanzilli, A., Pasqualetti, F., Lombardi, G., Vidiri, A., Gonnelli, A., Molinari, A., Cantarella, M., Bellu, L., Terrenato, I., Carosi, M., Maschio, M., Telera, S. M., Carapella, C. M., Cognetti, F., Paiar, F., Zagonel, V., & Pace, A. (2019). A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point? Future Oncology, 15(15), 1717-1727. https://doi.org/10.2217/fon-2018-0826

A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point? / Villani, Veronica; Fabi, Alessandra; Tanzilli, Antonio; Pasqualetti, Francesco; Lombardi, Giuseppe ; Vidiri, Antonello; Gonnelli, Alessandra; Molinari, Alessandro; Cantarella, Martina; Bellu, Luisa; Terrenato, Irene ; Carosi, Mariantonia ; Maschio, Marta ; Telera, Stefano Maria; Carapella, Carmine Maria; Cognetti, Francesco; Paiar, Fabiola; Zagonel, Vittorina ; Pace, Andrea.

In: Future Oncology, Vol. 15, No. 15, 01.05.2019, p. 1717-1727.

Research output: Contribution to journal › Article › peer-review

Villani, V, Fabi, A, Tanzilli, A, Pasqualetti, F, Lombardi, G , Vidiri, A, Gonnelli, A, Molinari, A, Cantarella, M, Bellu, L, Terrenato, I , Carosi, M , Maschio, M , Telera, SM, Carapella, CM, Cognetti, F, Paiar, F, Zagonel, V & Pace, A 2019, 'A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?', Future Oncology, vol. 15, no. 15, pp. 1717-1727. https://doi.org/10.2217/fon-2018-0826

Villani, Veronica ; Fabi, Alessandra ; Tanzilli, Antonio ; Pasqualetti, Francesco ; Lombardi, Giuseppe ; Vidiri, Antonello ; Gonnelli, Alessandra ; Molinari, Alessandro ; Cantarella, Martina ; Bellu, Luisa ; Terrenato, Irene ; Carosi, Mariantonia ; Maschio, Marta ; Telera, Stefano Maria ; Carapella, Carmine Maria ; Cognetti, Francesco ; Paiar, Fabiola ; Zagonel, Vittorina ; Pace, Andrea. / A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?. In: Future Oncology. 2019 ; Vol. 15, No. 15. pp. 1717-1727.

@article{0cc38010b2544cc9ac378a28894151be,

title = "A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: Clinical benefit is a plausible end point?",

abstract = "Aim: This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients & methods: The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months. Results: We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB. Conclusion: The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.",

keywords = "bevacizumab, clinical benefit, glioma",

author = "Veronica Villani and Alessandra Fabi and Antonio Tanzilli and Francesco Pasqualetti and Giuseppe Lombardi and Antonello Vidiri and Alessandra Gonnelli and Alessandro Molinari and Martina Cantarella and Luisa Bellu and Irene Terrenato and Mariantonia Carosi and Marta Maschio and Telera, {Stefano Maria} and Carapella, {Carmine Maria} and Francesco Cognetti and Fabiola Paiar and Vittorina Zagonel and Andrea Pace",

year = "2019",

month = may,

day = "1",

doi = "10.2217/fon-2018-0826",

language = "English",

volume = "15",

pages = "1717--1727",

journal = "Future Oncology",

issn = "1479-6694",